Meeting to be held on April 24 hosted by Oppenheimer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- Optimistic Buy Rating for PolyPid Driven by Clinical Progress and Financial Stability
- PolyPid’s Promising Outlook: Buy Rating Affirmed Amidst SHIELD II Trial Progress and Strategic FDA Engagement
- PolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection Prevention
- PolyPid completes enrollment in SHIELD II Phase 3 trial for D-PLEX100